ZVRA
Strong BuyUnloved QualityAI neutralZevra Therapeutics, Inc. · Healthcare · United States · $583M cap · $8.4M/day traded
$9.53 -2.9% · close 26 Oct · scored 27 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Report expected 4 Nov: the next-year EPS estimate has fallen 9.9% over the last 14 weeks.
As of 27 Oct 2026, MoatMap's StockRank for Zevra Therapeutics, Inc. (ZVRA) is 90/100, ranked against 24,000+ stocks in 35 markets (Quality 87, Value 65, Momentum 41, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Zevra Therapeutics sells MIPLYFFA, an approved treatment for the ultra-rare Niemann-Pick disease type C. Revenue rose 53% in the latest quarter, and the company is presenting long-term real-world data. Consensus estimates were revised up 2.5%. As a single-product rare-disease company, its outlook depends on patient identification, payer access and pipeline progress. Insider selling has been small.
ABOUT ZEVRA THERAPEUTICS, INC.
Read
Zevra Therapeutics, Inc. is a rare disease therapeutics company dedicated to developing and commercializing novel treatments for patients with unmet medical needs, particularly focusing on neurological and endocrine disorders. The company strategically targets highly specialized, underserved patient populations, leveraging orphan drug designations to create a competitive advantage. Zevra is focused on advancing late-stage clinical candidates and commercializing treatments that address significant gaps in care for rare diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.2M | 27.5M | 23.6M | 106.5M | 118.8% | 136.1M | 153.3M | 177.7M | 29.2% |
| EPS | -1.20 | -1.30 | -2.28 | 1.35 | — | 0.92 | 1.17 | 1.08 | -10.7% |
| Shares | 34.5M | 41.5M | 53.7M | 56.9M | +64.6% | 59.4M | — | — | — |
| Debt | 14.1M | 43.8M | 60.3M | 63.2M | 64.8% | — | — | — | — |
| Equity | 75.1M | 61.9M | 39.7M | 154.7M | 27.2% | — | — | — | — |
| Op CF | -18.7M | -33.5M | -69.7M | -1.6M | — | 33.4M | — | — | — |
| Inv CF | -36.7M | -17.4M | -22.2M | 18.1M | — | — | — | — | — |
| Fin CF | 8.4M | 28.5M | 82.1M | 12.1M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 75% of stocks we rank over the past year (60% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZVRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZVRA | Zevra Therapeutics, Inc.(you) | $583M | 90 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $569M | 97 | Strong Buy |
| CRMD | CorMedix Inc. | $612M | 98 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $644M | 81 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $387M | 94 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| QTTB | Q32 Bio Inc. | $258M | 88 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 98 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $571M | 62 | Hold |
Peer medians: ROE -30.5% · P/E 27.3x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.